On 9/16/24, Perspective Therapeutics Inc (NYSEAMERICAN: CATX) stock suffered a major decline of -13.1%, closing at $13.12. Moreover, this decline was accompanied by exceptionally high trading volume at 370% of normal. Relative to the market the stock has been exceptionally strong over the last nine months but has declined -14.0% during the last week.
Current PriceTarget Research Rating
CATX’s future returns on capital are forecasted to be in line with the cost of capital. Accordingly, the company is expected to be Value Creation neutral.
Perspective Therapeutics has a current Value Trend Rating of C (Low Neutral). This rating combines very contradictory signals from two proprietary PTR measures of a stock’s attractiveness. Perspective Therapeutics has a very low Appreciation Score of 1 but a very high Power Rating of 94, triggering the Low Neutral Value Trend Rating.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment